Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Gilead Sciences

Gilead Sciences Earns Membership In 95-Plus Composite Rating Club

Gilead Sciences saw its IBD SmartSelect Composite Rating rise to 96 Monday, up from 93 the day before.

Investors Business Daily

What to Expect From Gilead Sciences’ Q2 2025 Earnings Report

Gilead Sciences is expected to announce its fiscal second-quarter earnings next month, and analysts forecast a single-digit drop in its earnings.

Barchart

The Saturday Spread: Data-Driven Trades That Cut Through the Noise (GILD, MCD, DJT)

This weekend’s edition identifies three hot stocks that are flashing above-average upside probabilities with compelling multi-leg options strategies.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Gilead, Exact Jump After The Supreme Court Upholds A 'Cornerstone' Of Health Care

Gilead Sciences shares rose Friday after the Supreme Court tossed out a challenge that would have impacted HIV PrEP drugs.

Investors Business Daily

Trump Vows To Cut 'The Best Deal' On Drug Prices. What To Expect.

President Donald Trump, ever the negotiator, is angling to lower drug prices through his Most Favored Nation policy. But will it work? And will biotech stocks take a hit?

Investors Business Daily

US approves twice-yearly injection for HIV prevention – what you need to know about lenacapavir

The US Food and Drug Administration (FDA) has approved lenacapavir, an injectable drug that offers long-lasting protection against HIV infection. Administered once every six months, this new treatment marks a major advancement in expanding prevention options for people at risk of HIV infection.

The Conversation

Marjorie Taylor Greene Buys Stocks Focusing on Tech, Energy, and a Biotech Firm That Recently Received FDA Approval for HIV Drug

US Congress member Marjorie Taylor Greene purchased shares of Adobe, Netflix, Snowflake, ServiceNow, NextEra Energy, and Gilead Sciences on 6th June.

International Business Times UK

Read news from The Economist, FT, and more,
with one subscription

US Approves Gilead's Twice-yearly Injection To Prevent HIV

The US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV -- a move the company hailed as a major breakthrough in the fight against the sexually transmitted virus.

International Business Times

Gilead's HIV Prevention Drug Is 99.9% Effective. Could Politics Derail It?

Gilead Sciences won Food and Drug Administration approval Wednesday for a highly effective drug to prevent HIV infection.

Investors Business Daily

Is Gilead Sciences Stock Outperforming the S&P 500?

While Gilead Sciences has outperformed the S&P 500 Index over the past year, analysts are cautiously optimistic about the stock’s prospects.

Barchart

Alzheimer's and cold sores: Are they linked?

Could cold sores be linked to an increased risk of developing dementia? Could cold sore treatment be used to treat Alzheimer’s?

Evening Standard

Unusual Options Alert: The Smart Money is Piling Into Gilead Sciences (GILD)

While the new political paradigm might not be the most conducive environment for Gilead Sciences, positive sentiment is brewing for GILD stock.

Barchart

Stocks Flashing Renewed Technical Strength: Gilead Sciences

A Relative Strength Rating upgrade for Gilead Sciences shows improving technical performance.

Investors Business Daily

Gilead Sciences Clears Technical Benchmark, Hitting 90-Plus RS Rating

Gilead Sciences sees its Relative Strength Rating hit the elite 90-plus level.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

MarketBeat

3 Biotech Giants Gaining From U.S. Sales and Policy Shifts

The significant domestic revenue base of select US biotech companies offers stability potential for investors navigating global trade complexities.

Investors Business Daily

Gilead Dives As Its Biggest Moneymaker Misses. Here's Why It Could Still Be A 'Safe Haven' Stock.

Two of Gilead Sciences' most important drugs missed sales expectations late Thursday. Gilead stock fell early Friday.

The Conversation

Prison needle programs could save double what they cost – our new modelling shows how

Needle and syringe programs are a proven public health intervention that provide free, sterile injecting equipment to people who use drugs. By reducing needle sharing, these programs help prevent the spread of blood-borne viruses such as hepatitis C and HIV and minimise life-threatening bacterial infections.

Barchart

Here's What to Expect From Gilead Sciences’ Next Earnings Report

Gilead Sciences is expected to announce its fiscal first-quarter earnings this month, and analysts forecast a robust triple-digit in its earnings.

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

These 2 Buy-Rated Dividend Stocks Could Be Next in Line for a Trump Tariff Selloff. Should You Jump Ship Now?

Trump’s proposed tariffs on pharmaceutical imports from countries like Ireland and India have sparked concerns for companies like Amgen and Gilead Sciences.

Investors Business Daily

Gilead Dives As HHS Reportedly Mulls Cutting HIV Prevention Funding

Gilead stock tumbled Wednesday on reports HHS could slash federal funding for HIV prevention, a staple in Gilead Sciences' topline.

Barchart

Gilead Sciences - Leader in HIV Medicines

Summary Gilead Sciences (GILD) shows strong technical buy signals, with a 19.60% gain since Trend Seeker's buy signal on 1/27 and a 50.31% gain in the last year. The company offers a diverse portfolio of medicines for HIV, COVID-19, liver diseases, oncology, and more, with significant collaborations enhancing its pipeline....

MarketBeat

These 3 Dividend Stocks Jumped 15% in a Month—More to Come?

Dividend stocks aren't just for long-term income generation. These three shares have jumped 15% in one month while also offering dividend payouts.

The Conversation

5 years since COVID was declared a pandemic, we’re still poorly prepared for the next one

On March 11 2020, as COVID continued to spread rapidly around the globe, the World Health Organization (WHO) officially declared a pandemic.

MarketBeat

Gilead Sciences: 4 Reasons This Stock Has Much More To Rise

Gilead Pharmaceuticals is back to highs not seen in a decade as its HIV treatment franchise surges and awaits its 100% effective HIV prevention drug in summer

Investors Business Daily

Gilead Sciences Scores Relative Strength Rating Upgrade

Gilead Sciences sees its Relative Strength Rating hit the elite 90-plus level.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the World Health Organization

Food and Drug Administration

341 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.